Fig. 5
From: A polymeric nanocarrier that eradicates breast cancer stem cells and delivers chemotherapeutic drugs
The in vitro anti-BCCs and anti-BCSC efficacy of DOX/HA-b-PCDA NPs. (A-C) The cytotocixity of different drug formulations on the 4T1 BCCs (A) by MTT assay, noncancerous 293T cells by MTT assay (B), and BCSC-enriched 4T1 mammosphere cells by CCK-8 assay (C). (D) The effects of different drug formulations on disrupting already existing BCSC-enriched 4T1 mammosphere. a: control group, b: free DOX treated group, c: free DOX+free CUR treated group, d: free DOX+HA-b-PCDA treated group, e: DOX/HA-b-PCDA NPs treated group, scale bar=1 mm. (E) The effects of different drug formulations on preventing the secondary BCSC-enriched 4T1 mammospheres formation. a: control group, b: free DOX treated group, c: free DOX+free CUR treated group, d: free DOX+HA-b-PCDA treated group, e: DOX/HA-b-PCDA NPs treated group, scale bar=1 mm. (F) The effects of different drug formulations on eradicating of ALDHhigh cells in BCSC-enriched 4T1 mammospheres. a: control group, b: DOX treated group, c: DOX/HA-b-PCDA NPs treated group, d: HA-b-PCDA NPs treated group